Charities Fund UK–EU Research Partnerships
Organizations in the UK, Italy, and Spain distribute $39.4 million to six international cancer research projects.
NIH Budget Makes Up Ground
Agency sees a substantial boost for the fourth consecutive year, closes gap on medical inflation.
Technique Pinpoints Oncogenic BRCA1 Mutations
Effects of nearly 4,000 alterations catalogued.
Study: Atezolizumab Improves Survival in SCLC
Promising data for checkpoint inhibitor plus chemo could lead to new first-line treatment option for small cell lung cancer.
CAR T-cell Therapy for Solid Tumors?
Challenges abound, but researchers are investigating a variety of novel approaches.
Better Standards Sought for Predictive Immunotherapy Biomarkers
Initiatives aim to validate and harmonize assays that capture the inherent complexity of interactions between tumors and the immune system.
Two Win Nobel for Immune Regulation Discoveries
James Allison, PhD, and Tasuku Honjo, MD, PhD, will share the prestigious award for research on T-cell proteins CTLA4 and PD-1.
Hairy Cell Leukemia Treatment Approved
Moxetumomab pasudotox-tdfk generates high objective response rate, lasting responses.
New Partners to Develop Immune Engagers
Genentech/Affimed deal promotes research on antibody drugs that direct T cells and natural killer cells to tumors.
Histone Researchers Receive Lasker Award
Michael Grunstein, PhD, and C. David Allis, PhD, share prestigious prize.
Modified T Cells Home to Brain Tumors
Reengineered immune cells could improve CAR T-cell therapies for glioblastoma, medulloblastoma.
Osimertinib Treats CNS Metastases in NSCLC
The EGFR inhibitor bests gefitinib and erlotinib in combating lung cancer that spreads to the brain.
Illuminating Aberrant mRNA Events in CLL
Intronic polyadenylation is prevalent, generating truncated proteins that lack tumor-suppressive functions.
Cervical Cancer Screening Every 5 Years OK
New recommendations say HPV testing—without a Pap test—sufficient for most women.
With GBM, T Cells May Be Stuck in Bone Marrow
Sequestration driven by cell-surface S1P1 loss; findings suggest new therapeutic strategies for brain cancer.
Study Explains Specificity of CRISPR/Cas12a
Researchers find that alternate nuclease requires a closer DNA match than Cas9.